Eurofins Viracor, a provider in testing for infectious disease, immunology, and allergy, has launched a test that can assess the expansion and persistence of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.
CAR-T Therapy Test
The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients. CAR-T therapy is a form of immunotherapy that uses genetically engineered T-cells to attack cancer cells and has shown promising results in treating a variety of cancers.
Research has demonstrated that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy is likely to remain effective in the patient. The test is designed to provide clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient’s body and may offer insights to therapy effectiveness.
The test is designed to help clinicians make more informed decisions about the best course of treatment for their patients.
Eurofins Viracor is a subsidiary of Eurofins Scientific, a global provider in bio-analytical testing and genomic services.
Featured image: 3D illustration of T cells attacking a cancer cell. Photo: Dreamstime
